APY Aspyra,

Aspyra, Inc. (AMEX: APY) today announced the release of CyberLAB version 7.2.5, for general distribution to existing and new Laboratory Information System customers.

Aspyra’s CyberLAB LIS system is a scalable, feature-rich, and proven LIS solution for the hospital, clinic, and reference laboratory settings. CyberLAB LIS features decision support tools with auto-verification, automated clinical reporting and multisite management.

CyberLAB version 7.2.5 includes features that enhance the organization’s ability to connect and share data with multiple third party systems. This includes the capture and processing of incoming orders from more than one host system, such as Electronic Medical Records (EMR), Hospital Information System (HIS) or Practice Management System (PMS). By increasing the methods of order receipt, the laboratory can expand their business, increase patient sample volume and reduce medical errors with electronic order placement.

Jason Skolnick, Aspyra’s Director of Sales and Marketing, stated, “Interoperability and data sharing tools are critical components for today’s healthcare organizations.” He continued, “By adding additional features to our LIS for interfacing with EMRs and other host systems, we enable the laboratory to increase their community footprint and provide a higher level of patient care with immediate access to critical patient data.”

Aspyra solutions provide integrated technologies and services that improve the efficiency, safety and quality of patient care. Aspyra works directly with customers through its own sales and service staff as well as through an extensive partner network. The company currently counts over 440 customers and over 700 application installations in its installed base.

Safe Harbor Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to anticipated revenues, expenses, earnings, operating cash flows, the outlook for Aspyra’s markets and the demand for its products. Forward-looking statements are not guarantees of future performance and are inherently subject to uncertainties and other factors which could cause actual results to differ materially from the forward-looking statement. Such statements are based upon, among other things, assumptions made by, and information currently available to, management as of today the date of this press release, including management's own knowledge and assessment of the Company’s industry and competition. Factors that could cause Aspyra’s actual results to differ materially from these forward-looking statements include among others: the competitive environment; unexpected technical and marketing difficulties inherent in major product development efforts; the potential need for changes in our long-term strategy in response to future developments; future advances in clinical information technology and procedures, as well as potential changes in government regulations and healthcare policies; and rapid technological change in the microelectronics and software industries. The Company refers interested persons to its most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and its other SEC filings for a description of additional uncertainties and factors, which may affect forward-looking statements. The Company assumes no duty to update its forward-looking statements.

Aspyra (AMEX:APY)
Historical Stock Chart
From Nov 2024 to Dec 2024

Aspyra (AMEX:APY)
Historical Stock Chart
From Dec 2023 to Dec 2024